Announcements
- G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
- Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
- G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
- G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
- G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
More ▼
Key statistics
On Wednesday, G1 Therapeutics Inc (G1H:FRA) closed at 2.20, 112.75% above the 52 week low of 1.04 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.20 |
---|---|
High | 2.20 |
Low | 2.20 |
Bid | 2.32 |
Offer | 2.44 |
Previous close | 2.22 |
Average volume | 2.21k |
---|---|
Shares outstanding | 52.28m |
Free float | 46.72m |
P/E (TTM) | -- |
Market cap | 128.09m USD |
EPS (TTM) | -0.6146 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:00 BST.
More ▼